Plasma levels of CCL21, but not CCL19, independently predict future coronary events in a prospective population-based cohort.

Katra P, Hennings V, Nilsson J, Engström G, Engelbertsen D, Bengtsson E, Björkbacka H

Atherosclerosis 366 (-) 1-7 [2023-02-00; online 2023-01-12]

The homeostatic chemokines CCL21 and CCL19 have been explored as biomarkers in cardiovascular disease prediction in patients with established cardiovascular disease, but associations between these chemokines and first-time coronary event incidence have not been investigated before. Here, we explored associations between CCL21 or CCL19 and first-time incident coronary events in the general population-based Malmö Diet and Cancer cohort with two decades of follow-up. CCL21 and CCL19 levels in plasma were analysed with ELISA and proximity extension assay and associations with disease incidence were explored with conditional logistic regression in a nested case-control cohort (CCL21; n = 676) and with Cox regression in a population-based cohort (CCL19; n = 4636). High CCL21 levels in plasma were associated with incident first-time coronary events independently of traditional risk factors (odds ratio of 2.64 with 95% confidence interval 1.62-4.31, p < 0.001, comparing the highest versus the lowest tertile of CCL21), whereas CCL19 was not. CCL19 was, however, associated with incident heart failure, as well as increased all-cause, cardiovascular and cancer mortality independently of age and sex. Even though CCL21 and CCL19 both signal through CCR7, these chemokines may not be interchangeable as disease predictors and CCL21 could be used for prediction of future coronary events in individuals without any previous coronary heart disease history.

Affinity Proteomics Uppsala [Service]

PubMed 36652748

DOI 10.1016/j.atherosclerosis.2023.01.004

Crossref 10.1016/j.atherosclerosis.2023.01.004

pii: S0021-9150(23)00005-9